Samarendra K. Mohanty
Research Subjects
Samarendra K. Mohanty has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Michael Carlson
Nanoscope Therapeutics Inc, Dallas, USA
5 shared publicationsSubrata Batabyal
Nanoscope Therapeutics Inc, Dallas, USA
5 shared publicationsAnanta Ayyagari
Nanoscope Therapeutics Inc, 2777 N. Stemmons Fwy, Dallas, TX 75207, USA
3 shared publicationsKissaou Tchedre
Nanoscope Therapeutics, Inc., 2777 N. Stemmons Freeway, Dallas, TX 75207, USA
3 shared publicationsSamuel B. Barone
Nanoscope Therapeutics Inc, Dallas, USA
3 shared publicationsSanghoon Kim
Nanoscope Therapeutics Inc, Dallas, USA
3 shared publications
Latest Publications
- Open Access
- 4 June 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (6) , 660
Therapeutic Efficacy of Multi-Characteristic Opsin Gene Therapy in a Mouse Model of Stargardt Disease
Optogenetic gene therapy-based treatment offers a unique approach to bypass dysfunctional or degenerated photoreceptors in retinal degenerative disorders. Ambient light-activatable multi-characteristic opsin (MCO) targeted to bipolar cells of the retina has demonstrated partial vision restoration in animal models of retinitis pigmentosa (RP). Here, we describe the potential therapeutic efficacy of intravitreally delivered AAV-carried MCO-010 in a mouse model of Stargardt disease. MCO-010 treatment led to significantly improved behavioral outcomes in the visually guided radial arm water maze. Furthermore, longitudinal optical coherence tomographic imaging showed that the MCO-010 treatment led to no notable change in the retina thickness. Furthermore, the MCO-010-treated mice exhibited higher electrophysiological responses compared to the control group. Together, these findings demonstrate potential vision-restoring and disease-modifying aspects of ambient light-activatable intravitreal MCO-010 therapy.
- 4 June 2026
- Published by MDPI AG in Bioengineering
- Vol. 13 (6) , 660
Open AccessTherapeutic Efficacy of Multi-Characteristic Opsin Gene Therapy in a Mouse Model of Stargardt Disease
Optogenetic gene therapy-based treatment offers a unique approach to bypass dysfunctional or degenerated photoreceptors in retinal degenerative disorders. Ambient light-activatable multi-characteristic opsin (MCO) targeted to bipolar cells of the retina has demonstrated partial vision restoration in animal models of retinitis pigmentosa (RP). Here, we describe the potential therapeutic efficacy of intravitreally delivered AAV-carried MCO-010 in a mouse model of Stargardt disease. MCO-010 treatment led to significantly improved behavioral outcomes in the visually guided radial arm water maze. Furthermore, longitudinal optical coherence tomographic imaging showed that the MCO-010 treatment led to no notable change in the retina thickness. Furthermore, the MCO-010-treated mice exhibited higher electrophysiological responses compared to the control group. Together, these findings demonstrate potential vision-restoring and disease-modifying aspects of ambient light-activatable intravitreal MCO-010 therapy.
- 13 March 2026
- Published by Springer Nature in Documenta Ophthalmologica
- Vol. 153 (1) , 1-18
Validation of a novel multi-luminance shape discrimination test for assessment of functional vision
Background In low-vision patients, traditional measures often fall short of capturing functional vision improvements. The study aims to assess the reliability and validity of a novel functional low-vision outcome assessment, the Multi-luminance Shape Discrimination Test (MLSDT). Methods This is a prospective, observational study in 25 participants with severe vision loss due to retinitis pigmentosa (RP) with visual acuity worse than or equal to LogMAR 1.6, and in 10 normal vision participants. The MLSDT utilizes three differently shaped objects, randomly positioned on pressure sensors, to enable an automated, quantifiable response in a controlled multi-luminance environment. The assessment accuracy (recognizing the correct object and picking it up) was measured using the MLSDT. Convergent validity of MLSDT was evaluated with measures of visual acuity and visual field, as well as patient-reported outcomes. Results The 35 study participants (60% male and 40% female) had a mean age of 46.5 years old (range: 19–78 years), with 24 Hispanic individuals. Estimates of test–retest reliability for MLSDT exceeded 0.50. The correlations between MLSDT test scores and LogMAR visual acuity were strong (> -0.7). For a difference of 0.3 LogMAR between the groups of RP participants, a decrease of ~ 2-level MLSDT score was observed. Moderate to strong correlations were also observed between MLSDT test scores and the measures of visual field and patient-reported outcome measures. Conclusion Psychometric evaluation demonstrates the reliability and validity of the novel functional vision endpoint, MLSDT. The MLSDT test performance in participants with different visual acuities showed improved object recognition when the luminance level was enhanced.
- 13 March 2026
- Published by Springer Nature in Documenta Ophthalmologica
- Vol. 153 (1) , 1-18
Validation of a novel multi-luminance shape discrimination test for assessment of functional vision
Background In low-vision patients, traditional measures often fall short of capturing functional vision improvements. The study aims to assess the reliability and validity of a novel functional low-vision outcome assessment, the Multi-luminance Shape Discrimination Test (MLSDT). Methods This is a prospective, observational study in 25 participants with severe vision loss due to retinitis pigmentosa (RP) with visual acuity worse than or equal to LogMAR 1.6, and in 10 normal vision participants. The MLSDT utilizes three differently shaped objects, randomly positioned on pressure sensors, to enable an automated, quantifiable response in a controlled multi-luminance environment. The assessment accuracy (recognizing the correct object and picking it up) was measured using the MLSDT. Convergent validity of MLSDT was evaluated with measures of visual acuity and visual field, as well as patient-reported outcomes. Results The 35 study participants (60% male and 40% female) had a mean age of 46.5 years old (range: 19–78 years), with 24 Hispanic individuals. Estimates of test–retest reliability for MLSDT exceeded 0.50. The correlations between MLSDT test scores and LogMAR visual acuity were strong (> -0.7). For a difference of 0.3 LogMAR between the groups of RP participants, a decrease of ~ 2-level MLSDT score was observed. Moderate to strong correlations were also observed between MLSDT test scores and the measures of visual field and patient-reported outcome measures. Conclusion Psychometric evaluation demonstrates the reliability and validity of the novel functional vision endpoint, MLSDT. The MLSDT test performance in participants with different visual acuities showed improved object recognition when the luminance level was enhanced.
- Open Access
- 14 August 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 87, 103430
Safety and efficacy of MCO-010 optogenetic therapy in patients with Stargardt disease in USA (STARLIGHT): an open-label multi-center Ph2 trial
- 14 August 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 87, 103430
Open AccessSafety and efficacy of MCO-010 optogenetic therapy in patients with Stargardt disease in USA (STARLIGHT): an open-label multi-center Ph2 trial
- Open Access
- 24 April 2025
- Published by Elsevier in Molecular Therapy
- Vol. 33 (5) , 1868
Response: Promise and open questions of optogenetic vision restoration by MCO
- 24 April 2025
- Published by Elsevier in Molecular Therapy
- Vol. 33 (5) , 1868
Open AccessResponse: Promise and open questions of optogenetic vision restoration by MCO
- Top Cited PapersOpen Access
- 22 March 2025
- Published by Elsevier in Molecular Therapy
- Vol. 33 (5) , 2279-2290
A synthetic opsin restores vision in patients with severe retinal degeneration
- 22 March 2025
- Published by Elsevier in Molecular Therapy
- Vol. 33 (5) , 2279-2290
Top Cited PapersOpen AccessA synthetic opsin restores vision in patients with severe retinal degeneration
- Open Access
- 1 October 2024
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Translational Vision Science & Technology
- Vol. 13 (10) , 25
Multi-Characteristic Opsin Therapy to Functionalize Retina, Attenuate Retinal Degeneration, and Restore Vision in Mouse Models of Retinitis Pigmentosa
Purpose: Retinal degeneration 1 and 10 (rd1 and rd10) mice are useful animal models of retinitis pigmentosa (RP) with rapidly and slowly progressive pathologies, respectively. Our study aims were to determine the effect of adeno-associated viral vector 2 (AAV2)-delivered multi-characteristic opsin (MCO-010; under the control of a metabotropic glutamate receptor-6 promoter enhancer) on the morphological and functional characteristics of vision in both rd1 and rd10 mice. Methods: Various retinal measures of MCO-010 transduction and electrophysiological, behavioral, and other routine blood analyses were performed in the rd1 and/or rd10 mice after intravitreal injection of 1 µL of MCO-010 or AAV2 vehicle. Functional tests included electroretinogram, visually evoked potential, and behavior assay (optomotor and water maze). Retinal thickness, intraocular pressure, and plasma cytokine levels were also determined. Results: Following intravitreal MCO-010 injection, approximately 80% of bipolar cells were transduced in the retina, and no alterations in retinal thickness were observed at 4 months post-injection. However, retinal thickness significantly decreased in control mice. MCO-010 treatment increased head movements and induced faster navigation of mice to the platform in a water-maze test. The MCO-010 gene therapy helped preserve visually evoked electrical response in the retina and visual cortex. No ocular toxicity, immunotoxicity, or phototoxicity was observed in the MCO-010–treated mice, even under chronic intense light conditions. Conclusions: Intravitreal MCO-010 was well tolerated in rd1 and rd10 mice models of RP, and it appeared to attenuate retinal photoreceptor degeneration based on retinal structure and functional outcome measures. Translational Relevance: As reported here, optogenetic treatment of the inner retina attenuates further retinal degeneration in addition to photosensitizing higher order neurons, and this disease-modifying aspect should be evaluated in optogenetic clinical trials.
- 1 October 2024
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Translational Vision Science & Technology
- Vol. 13 (10) , 25
Open AccessMulti-Characteristic Opsin Therapy to Functionalize Retina, Attenuate Retinal Degeneration, and Restore Vision in Mouse Models of Retinitis Pigmentosa
Purpose: Retinal degeneration 1 and 10 (rd1 and rd10) mice are useful animal models of retinitis pigmentosa (RP) with rapidly and slowly progressive pathologies, respectively. Our study aims were to determine the effect of adeno-associated viral vector 2 (AAV2)-delivered multi-characteristic opsin (MCO-010; under the control of a metabotropic glutamate receptor-6 promoter enhancer) on the morphological and functional characteristics of vision in both rd1 and rd10 mice. Methods: Various retinal measures of MCO-010 transduction and electrophysiological, behavioral, and other routine blood analyses were performed in the rd1 and/or rd10 mice after intravitreal injection of 1 µL of MCO-010 or AAV2 vehicle. Functional tests included electroretinogram, visually evoked potential, and behavior assay (optomotor and water maze). Retinal thickness, intraocular pressure, and plasma cytokine levels were also determined. Results: Following intravitreal MCO-010 injection, approximately 80% of bipolar cells were transduced in the retina, and no alterations in retinal thickness were observed at 4 months post-injection. However, retinal thickness significantly decreased in control mice. MCO-010 treatment increased head movements and induced faster navigation of mice to the platform in a water-maze test. The MCO-010 gene therapy helped preserve visually evoked electrical response in the retina and visual cortex. No ocular toxicity, immunotoxicity, or phototoxicity was observed in the MCO-010–treated mice, even under chronic intense light conditions. Conclusions: Intravitreal MCO-010 was well tolerated in rd1 and rd10 mice models of RP, and it appeared to attenuate retinal photoreceptor degeneration based on retinal structure and functional outcome measures. Translational Relevance: As reported here, optogenetic treatment of the inner retina attenuates further retinal degeneration in addition to photosensitizing higher order neurons, and this disease-modifying aspect should be evaluated in optogenetic clinical trials.